Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + carfilzomib + dexamethasone in relapsed/refractory multiple myeloma
2019-004340-30Phase 2Active
- Sponsor
- AbbVie Inc.
- Start
- Apr 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax, carfilzomib and dexamethasone in multiple myeloma (MM), sponsored by AbbVie Inc. Primary endpoint: Safety and tolerability of venetoclax + carfilzomib + dexamethasone. Started Apr 2020; status: active.
02
Drugs
venetoclaxcarfilzomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2019-004340-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004340-30.